[117 Pages Report] The organs-on-chips market is expected to reach USD 45.6 Million by 2022 from USD 9.6 Million in 2017, at a CAGR of 36.6%. The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and new products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.

This report segments the organs-on-chips market into type, offerings, application, end user, and region. Based on type, the organs-on-chips market is segmented into liver, lung, heart, kidney, and other organs-on-chips. In 2017, the accessories segment is expected to account for the largest share of the organs-on-chips market. The large share of this segment can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to the in vivo environment.

Based on application, the organs-on-chips market is segmented into physiological model development, drug discovery, and toxicology research. The drug discovery segment is expected to register the highest CAGR during the forecast period.

In 2017, North America is expected to account for the largest share and also expected to grow at the highest CAGR of the market followed by Europe. The largest share and high growth of this market is attributed to the factors such as the availability of new and advanced organs-on-chips models in the market, favorable government initiatives in terms of funding and programs for basic drug development and research, and the presence of key pharmaceutical companies.

Issues related to the incorporation of organs-on-chips technologies into existing workflows, and complexity of organs-on-chips models may limit market growth to a certain extent in the coming years. The organs-on-chips market is emerging and competitive in nature, with a number of small players competing for market space (including startups firms). Prominent players in this market include Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), Ascendance Bio (US), CN Bio (UK), TissUse (Germany), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst